FDA approves aplastic Eylea (aflibercept) to treat all stages of diabetic retinopathy

today,the u.SFDA(http://approved the company's Eylea (dr) for the treatment of diabetic dysleuretic lesions at all stages to reduce a patient's risk of blindness, http:// announced todayAbout Eylea
Eylea is an vascular endothelial growth factor (VEGF) inhibitorIt inhibits vascular hyperplasia and reduces vascular permeability by inhibiting the signaling pathways mediated by VEGF-A and placental growth factor (PLGF)before enough, Eylea had received FDA approval to treat eye diseases such as wet age-associated macular degeneration (AMD), diabetic macular edema (DME)the study
this approval is based on Eylea's performance in the(http://of a Phase 3 clinicaltrial called PANORAMAIn this trial, 402 patients with moderate to severe NPDR were treated with Eylea injections or false injections in the glass body These patients have not yet developed DME The patients were divided into three groups, each receiving an Eylea injection, or a false injection, at each of the 8 or 16 weeks 　　The results showed that Eylea reached the main end of the trial: after one year of treatment, the proportion of retinal lesions in eylea treatment group improved significantly higher than in the control group Using the DRSS scale, the two groups treated with Eylea improved their DRSS scores at 65% (once every 16 weeks) and 80% (every 8 weeks) The control group had a value of 15% 　　Eylea reduced the risk of developing a patient's disease into a PDR or a pre-neonatal blood vessel (anterior segment neovascularization, ASNV) by 85% (once every 16 weeks) and 88% (every 8 weeks)